Trial · NCT02872857

Subarachnoid Hemorrhage Recovery And Galantamine

NCT02872857, Phase 1, Phase 2, Completed, The University of Texas Health Science Center, Houston; results first posted 2021-10-08

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Subarachnoid Hemorrhage Recovery And Galantamine. Trials, record NCT02872857. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02872857

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Subarachnoid Hemorrhage Recovery And Galantamine
NCT number: NCT02872857
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 60 participants, actual
Lead sponsor: The University of Texas Health Science Center, Houston
Conditions: Subarachnoid Hemorrhage
Interventions: Placebo, 8mg galantamine twice daily, 12mg galantamine twice daily
First posted: 2016-08-19
Last updated: 2021-10-08
Results first posted: 2021-10-08

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug	90 days
Primary	Mortality	90 days
Primary	Modified Rankin Score	90 days	The Modified Rankin Score (mRS) is scored as follows: 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead.
Secondary	Montreal Cognitive Assessment (MoCA)	baseline (in hospital)	MoCA scores range between 0 and 30. Higher scores indicate a better outcome, and a score of 26 or over is considered to be normal.
Secondary	Montreal Cognitive Assessment (MoCA)	90 days	MoCA scores range between 0 and 30. Higher scores indicate a better outcome, and a score of 26 or over is considered to be normal.
Secondary	EuroQOL Score as Assessed by a Visual Analogue Scale (VAS)	90 days	In the EuroQOL VAS assessment, health status is marked on a 20 cm vertical scale with end points of 0 and 100. 0 corresponds to " the worst health you can imagine," and 100 corresponds to "the best health you can imagine."

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug	90 days	Because of the small sample size of this study, which is underpowered to detect differences between the 8mg and 12mg galantamine arms, the pre-specified analysis approach was to combine data for the two galantamine arms when comparing to the placebo arm.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Mortality	90 days	Because of the small sample size of this study, which is underpowered to detect differences between the 8mg and 12mg galantamine arms, the pre-specified analysis approach was to combine data for the two galantamine arms when comparing to the placebo arm.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Modified Rankin Score	90 days	Data was not collected for 3 in the galantamine arm and 2 in the placebo arm. Because of the small sample size of this study, which is underpowered to detect differences between the 8mg and 12mg galantamine arms, the pre-specified analysis approach was to combine data for the two galantamine arms when comparing to the placebo arm.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Montreal Cognitive Assessment (MoCA)	baseline (in hospital)	Data was not collected for 1 in the galantamine arm and 6 in the placebo arm. Because of the small sample size of this study, which is underpowered to detect differences between the 8mg and 12mg galantamine arms, the pre-specified analysis approach was to combine data for the two galantamine arms when comparing to the placebo arm.	score on a scale	MEAN
SECONDARY	Montreal Cognitive Assessment (MoCA)	90 days	Data was not collected for 6 in the galantamine arm and 6 in the placebo arm. Because of the small sample size of this study, which is underpowered to detect differences between the 8mg and 12mg galantamine arms, the pre-specified analysis approach was to combine data for the two galantamine arms when comparing to the placebo arm.	score on a scale	MEAN
SECONDARY	EuroQOL Score as Assessed by a Visual Analogue Scale (VAS)	90 days	Data was not collected for 5 in the galantamine arm and 6 in the placebo arm. Because of the small sample size of this study, which is underpowered to detect differences between the 8mg and 12mg galantamine arms, the pre-specified analysis approach was to combine data for the two galantamine arms when comparing to the placebo arm.	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug	Galantamine		1	Participants
Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug	Placebo		1	Participants
Mortality	Galantamine		1	Participants
Mortality	Placebo		4	Participants
Modified Rankin Score	Galantamine	0	3	Participants
Modified Rankin Score	Placebo	0	2	Participants
Modified Rankin Score	Galantamine	1	8	Participants
Modified Rankin Score	Placebo	1	2	Participants
Modified Rankin Score	Galantamine	2	4	Participants
Modified Rankin Score	Placebo	2	12	Participants

1 to 10 of 24Source ClinicalTrials.gov

See all 24 results by group

Participant flow24

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Phase 1	STARTED	Galantamine 8mg During Phase 1	15
Phase 1	STARTED	Placebo During Phase 1	15
Phase 1	STARTED	Galantamine 12mg During Phase 2	0
Phase 1	STARTED	Placebo During Phase 2	0
Phase 1	COMPLETED	Galantamine 8mg During Phase 1	15
Phase 1	COMPLETED	Placebo During Phase 1	15
Phase 1	COMPLETED	Galantamine 12mg During Phase 2	0
Phase 1	COMPLETED	Placebo During Phase 2	0
Phase 1	NOT COMPLETED	Galantamine 8mg During Phase 1	0
Phase 1	NOT COMPLETED	Placebo During Phase 1	0

1 to 10 of 24Source ClinicalTrials.gov

See all 24 participant flow

Adverse events50

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	Galantamine	13	30	13
other	Anemia	Blood and lymphatic system disorders	Placebo	12	30	12
other	Hyponatremia	Metabolism and nutrition disorders	Galantamine	12	30	12
other	Hyponatremia	Metabolism and nutrition disorders	Placebo	11	30	12
other	Bradycardia	Cardiac disorders	Galantamine	10	30	10
other	Bradycardia	Cardiac disorders	Placebo	12	30	12
other	Pneumonia	Respiratory, thoracic and mediastinal disorders	Galantamine	7	30	9
other	Pneumonia	Respiratory, thoracic and mediastinal disorders	Placebo	6	30	6
other	Hypernatremia	Metabolism and nutrition disorders	Galantamine	7	30	7
other	Hypernatremia	Metabolism and nutrition disorders	Placebo	11	30	11

1 to 10 of 50Source ClinicalTrials.gov

See all 50 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Galantamine	1	30
Total, all-cause mortality	Placebo	4	30
Total, other adverse events	Galantamine	26	30
Total, other adverse events	Placebo	29	30
Total, serious adverse events	Galantamine	17	30
Total, serious adverse events	Placebo	17	30

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
40877496	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Galantamine vs Placebo: Mortality	Trial comparisons
Galantamine vs Placebo: deaths from any cause	Trial comparisons
Galantamine vs Placebo: Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug	Trial comparisons
Galantamine vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02872857

GET https://conductscience.org/api/trials/v1/NCT02872857/results?page=2

API reference For AI assistants